Efficacy and safety of omalizumab in moderate to severe allergic asthma: a prospective study

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2000029142

Enrollment

Unknown

Registered

2020-01-15

Start date

2020-04-01

Completion date

Unknown

Last updated

2020-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

moderate to severe allergic asthma

Interventions

Case series:Subcutaneous injection of omalizumab

Control group:Conventional treatment

Eligibility

Sex/Gender

All

Age

14 Years to 85 Years

Inclusion criteria

Inclusion criteria: (1) Sign the informed consent; (2) Clinical diagnosis of severe allergic asthma; (3) Total allergen IgE> 30IU / mL or serum allergen-specific IgE> 0.35IU / mL; (4) First use of omazumab; (5) At least one acute exacerbation in the past year.

Exclusion criteria

Exclusion criteria: (1) Previous treatment with omazumab; (2) Patients with immunodeficiency or patients who have used immunoglobulin; (3) Malignant tumor; (4) Asthma and chronic obstructive pulmonary disease overlap.

Design outcomes

Primary

Measure	Time frame
exacerbations;	—

Secondary

Measure	Time frame
reduction of oral corticosteroids;adverse events;lung function;fractional exhaled nitric oxide;Blood eosinophil count;asthma control test;	—

Countries

China

Contacts

Public ContactWen Wang

Beijing Chaoyang Hospital affiliated to Capital University of Medical

wenwang318@126.com+86 13691362565

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026